Recombinant human erythropoietin protects against immature brain damage induced by hypoxic/ischemia insult

Neuroreport. 2023 Dec 6;34(17):801-810. doi: 10.1097/WNR.0000000000001957. Epub 2023 Oct 18.

Abstract

To investigate the neuroprotection of recombinant human erythropoietin (rhEPO) against hypoxic/ischemic (HI) insult in three-day-old rats. Postnatal day 3 (PD3) rats were randomly divided into three groups: Sham group, HI group and HI+rhEPO group. Ligation of the right common carotid artery and hypoxia to induce HI brain injury. After HI insult, the rats received intraperitoneal injection of rhEPO (5000 IU/Kg, qod) in HI+rhEPO group or equal saline in other groups. On PD10, damage of brain tissue was examined by hematoxylin-eosin (HE) staining, observation of neuronal apoptosis in the hippocampus and cortex using immunofluorescence assay (marker: TUNEL). Immunohistochemical staining or western blotting was performed to detect the expression of cyclooxygenase-2 (COX-2), Caspase-3 and phosphorylated Akt (p-Akt) protein. On PD28, cognitive ability of rats was assessed by Morris water maze test. HI injury causes brain pathological morphology and cognitive function damage in PD3 rats, which can be alleviated by rhEPO intervention. Compared with the HI group, the HI+rhEPO group showed an increase in platform discovery rate and cross platform frequency, while the search platform time was shortened (P < 0.05). The proportion of TUNEL positive neurons and the expression of COX-2 and Caspase-3 proteins in brain tissue in the hippocampus and cortex was decreased, while the expression of p-Akt protein was upregulated (P < 0.05). RhEPO could protect against the pathological and cognitive impairment of immature brain induced by HI insult. This neuroprotective activity may involve in inhibiting inflammatory and apoptosis by activation of PI3K/Akt signaling pathway.

MeSH terms

  • Animals
  • Animals, Newborn
  • Brain / metabolism
  • Caspase 3 / metabolism
  • Cyclooxygenase 2 / metabolism
  • Erythropoietin* / pharmacology
  • Erythropoietin* / therapeutic use
  • Humans
  • Hypoxia / metabolism
  • Hypoxia-Ischemia, Brain* / complications
  • Hypoxia-Ischemia, Brain* / drug therapy
  • Hypoxia-Ischemia, Brain* / metabolism
  • Ischemia / metabolism
  • Neuroprotective Agents* / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Caspase 3
  • Proto-Oncogene Proteins c-akt
  • Cyclooxygenase 2
  • Phosphatidylinositol 3-Kinases
  • Erythropoietin
  • Neuroprotective Agents